Low molecular weight heparin versus unfractionated heparin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention with drug-eluting stents

摘要: Summary Background Whether low molecular weight heparin (LMWH) enoxaparin is equivalent to unfractionated (UFH) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention (PCI) drug-eluting stents (DES) remains unclear. Methods A total of 2397 NSTEMI who underwent PCI DES received either LMWH [ n  = 1178, subcutaneous 1 mg/kg, b.i.d., initiated after the patient's arrival and continued until 3–5 days plus reduced dose UFH (50–70 U/kg) during PCI] or (  = 1219, 24,000 U/day infusion, at least 48 h PCI). The bleeding events clinical outcomes in-hospital 8 months were compared. Results Enoxaparin group had similar incidences cardiac death, major adverse (MACE) compared group. minor also between two groups. Multivariable Cox regression analysis showed that death [adjusted odds ratio (OR) 1.16, 95% confidence interval (CI) 0.64–2.10, p  = 0.620], (adjusted OR 1.08, CI 0.66–1.76,  = 0.760), MACE 0.94, 0.69–1.28,  = 0.692) as Conclusions only an adjunctive antithrombotic therapy was safe comparable 8-month alone.